AGL Company Profile and Key Details

AGL has shown mixed momentum, losing -0.98% over the past week and 1.75% over the past quarter, though year-to-date performance is up 41.82%. Short-term trend indicators are bullishly aligned (SMA20 -10.28%, SMA50 -30.19%, SMA200 -60.64%). The stock’s 14-day RSI is 42.44 (neutral), while the ATR of 0.07 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -91.78% below its high and over 48.15% above its low. Average 10-day trading volume of 7.27 million shares is in line with the 3-month average of 7.45 million, indicating normal recent market interest.

Agilon Health, Inc. has 414.58 million shares outstanding. The public float is 270.44 million shares, elevated short interest at 7.96% of float. This equals 20.18 million shares. The short ratio is 3.25 days. Institutional investors hold 94.69% of the float. Insiders own 2.08%. CD&R Vector Holdings, L.P. holds 194.61 million shares, CD&R Investment Associates IX, Ltd. has 100.00 million shares and Shaker Benjamin has 461.20 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Agilon Health, Inc. generated EPS of -$0.78 over the past year. Five-year average earnings growth is 3.29%. Wall Street analysts project EPS growth of 26.67% annually over the next five years. The latest quarter delivered EPS of -$0.27. The next quarter is forecast at -$0.27. Next year's EPS is expected at $128.08. Analyst sentiment is neutral. Analyst rating data shows there are 4 Strong Buy ratings, 1 Buy ratings, 6 Hold ratings, 0 Sell rating and 2 Strong Sell ratings. Price targets range from $8.50 to $1.00. The high target offers 1600.0% upside. The low target suggests 100.0% downside. The mean target is $2.23. This offers 346.0% upside. Agilon Health, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 04, 2025, missed forecasts by 50.0%. The prior quarter beat by 127.27%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in August 06, 2024.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Agilon Health, Inc. (NYSE:AGL) closed at $0.50 USD, gaining $0.11 (26.90%) from the previous close of $0.39. The stock is currently mid-range between its 52-week high and low $0.34 and $6.08. With a market capitalization of about $207.29 million, Agilon Health, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.07). Key stats such as the average daily volume over the past year has been around 7.78 million shares, in line with its 52-week average. Headquartered in Austin, TX, Agilon Health, Inc. operates in the Healthcare sector and the Medical - Care Facilities industry. Led by CEO Ronald Allan Williams, the company employs approximately 1,076 people and listed since April 15, 2021. agilon health, inc. offers healthcare services for seniors through primary care physicians in the communities of the United States.

Agilon Health, Inc. trades at a P/E ratio of -0.69, slightly below the S&P 500 average, with a price-to-sales ratio of 0.04 and a price-to-book ratio of 0.7 suggesting the stock is closer to book value. The P/FCF stands at -2.17, also above market averages.

Agilon Health, Inc. (NYSE:AGL) shares are up 41.82% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Agilon Health, Inc. trading at a premium to the broader market with a P/E of -0.69. Analyst sentiment is cautious, with the majority of ratings in Underweight territory and a mean price target of $15.59, suggesting 3018.0% upside. Our AI forecast model points to short-term weakness (-58.0% over two weeks), a medium-term fall (-66.0% over three months), and a longer-term loss (-88.0% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Agilon Health, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -58.0%, with price expected at $0.21 by March 10, 2026, within a range of $0.02 to $0.37 3-Month Outlook: Projected fall of -66.0%, reaching $0.17 by May 25, 2026, with a range of $0.07 to $0.28. 1-Year Outlook: Projected loss of -88.0%, with price at $0.06 by February 24, 2027, within a range of $0.00 to $0.00.